OxTalks will soon be transitioning to Oxford Events (full details are available on the Staff Gateway). A two-week publishing freeze is expected in early Hilary to allow all events to be migrated to the new platform. During this period, you will not be able to submit or edit events on OxTalks. The exact freeze dates will be confirmed as soon as possible.
If you have any questions, please contact halo@digital.ox.ac.uk
Background:
Psilocybin has demonstrated apparent antidepressant effects in pilot studies with depressed patients, but RCT evidence for its effect in treatment-resistant depression has been lacking. Treatment resistance is common, carries significant morbidity and next step treatments are often unsatisfactory.
Methods:
We performed a double-blind, parallel-group trial to evaluate the safety and efficacy of psilocybin in adults with treatment-resistant major depressive disorder, randomized 1:1:1 to a single dose of psilocybin (25mg, 10mg, 1mg), with psychological support.
Results:
A total of 79 patients were assigned to psilocybin 25mg, 75mg, 10mg, and 79 to 1 mg. Mean week 3 change in the MADRS for psilocybin 25 mg and 10 mg dose groups versus 1 mg were – 12.0 and -7.9 versus -5.4 points (least-squares mean difference for the 25 mg and 10 mg doses versus the 1 mg dose was -6.6 points: 95% CI, -10.2 to 2.9, P<0.001; and -2.5 points, 95% CI, -6,2 to 1.2; not significant). Sustained response rates at week 12 were 34.8% for psilocybin 25mg, 9.1% for 10 mg, and 18.2% for 1 mg. The number of patients discontinuing due to an adverse event on psilocybin 25 mg, 10 mg and 1 mg was n=2,2, and 4, respectively. The relationship between positive psychedelic experience and clinical outcomes supports the dose-related effect seen in the primary analysis.
Conclusions:
The efficacy and acceptability demonstrated in this Phase IIb trial support the further development of psilocybin for treatment-resistant depression. The proposed phase 3 clinical programme will be described.
